newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

  • IGC Pharma announced that the Canadian Intellectual Property Office issued a Notice of Allowance for patent No. 3,095,729 covering the proprietary composition of IGC-AD1.
  • The allowance secures composition protection for IGC-AD1 across key North American jurisdictions, reinforcing long-term exclusivity for the low-dose combination therapy.
  • The Phase 2 CALMA trial for agitation associated with Alzheimer's disease has completed approximately 70% of its planned enrollment.
  • CEO Ram Mukunda stated that the patent coverage strengthens the strategic foundation & commercial positioning of the program as it advances toward enrollment completion.
  • IGC-AD1 is a multi-target formulation utilizing low doses of THC & other ingredients, differentiated from single-target approaches.
  • IGC Pharma is a clinical-stage company leveraging AI to develop treatments for Alzheimer's & metabolic disorders, with a pipeline including lead asset IGC-AD1 & candidate TGR-63.